Acasti Pharma reported $21.31M in Cash and Equivalent for its fiscal quarter ending in September of 2026.





Cash And Equivalent Change Date
Acasti Pharma USD 21.31M 7.56M Sep/2026
Addus HomeCare USD 98.48M 1.09M Sep/2026
Amarin USD 156.51M 12.95M Sep/2026
Cassava Sciences USD 46.99M 35.69M Sep/2026
Knight Therapeutics CAD 76.45M 5.43M Dec/2025
Option Care Health USD 299.09M 105.33M Sep/2026
Organigram Holdings CAD 10.85M 6.56M Jun/2026
Tilray USD 264.83M 43.16M Jun/2025